Build Your Comparison

Side-by-side financial analysis
BLLN logo
BLLN
PGNY logo
PGNY
Try popular comparisons:

Stock Comparison

BLLN vs PGNY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BLLN
BillionToOne, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.65B
5Y Perf.-1.5%
PGNY
Progyny, Inc.

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$2.09B
5Y Perf.-16.2%

BLLN vs PGNY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BLLN logoBLLN
PGNY logoPGNY
IndustryMedical - Diagnostics & ResearchMedical - Healthcare Information Services
Market Cap$4.65B$2.09B
Revenue (TTM)$355M$1.29B
Net Income (TTM)$25M$68M
Gross Margin70.4%24.1%
Operating Margin10.2%7.5%
Forward P/E102.7x20.8x
Total Debt$109M$24M
Cash & Equiv.$496M$112M

Quick Verdict: BLLN vs PGNY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PGNY leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. BillionToOne, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇PGNY emerged as the overall leader. Track its performance:
BLLN
BillionToOne, Inc.
The Growth Play

BLLN is the clearest fit if your priority is growth exposure.

  • Rev growth 100.0%, EPS growth 106.8%
  • 100.0% revenue growth vs PGNY's 10.4%
  • 7.1% margin vs PGNY's 5.2%
Best for: growth exposure
PGNY
Progyny, Inc.
The Income Pick

PGNY carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 0.61
  • 67.1% 10Y total return vs BLLN's -7.2%
  • Lower volatility, beta 0.61, Low D/E 4.7%, current ratio 2.73x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBLLN logoBLLN100.0% revenue growth vs PGNY's 10.4%
ValuePGNY logoPGNYLower P/E (20.8x vs 102.7x)
Quality / MarginsBLLN logoBLLN7.1% margin vs PGNY's 5.2%
Stability / SafetyPGNY logoPGNYBeta 0.61 vs BLLN's 1.91, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)PGNY logoPGNY+23.6% vs BLLN's -7.2%
Efficiency (ROA)PGNY logoPGNY9.0% ROA vs BLLN's 5.1%, ROIC 18.1% vs 13.5%

BLLN vs PGNY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

BLLNBillionToOne, Inc.

Segment breakdown not available.

PGNYProgyny, Inc.
FY 2025
Fertility benefit services revenue
64.5%$831M
Pharmacy benefit services revenue
35.5%$458M

BLLN vs PGNY — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPGNYLAGGINGBLLN

Income & Cash Flow (Last 12 Months)

BLLN leads this category, winning 5 of 6 comparable metrics.

PGNY is the larger business by revenue, generating $1.3B annually — 3.6x BLLN's $355M. Profitability is closely matched — net margins range from 7.1% (BLLN) to 5.2% (PGNY). On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBLLN logoBLLNBillionToOne, Inc.PGNY logoPGNYProgyny, Inc.
RevenueTrailing 12 months$355M$1.3B
EBITDAEarnings before interest/tax$44M$100M
Net IncomeAfter-tax profit$25M$68M
Free Cash FlowCash after capex$28M$181M
Gross MarginGross profit ÷ Revenue+70.4%+24.1%
Operating MarginEBIT ÷ Revenue+10.2%+7.5%
Net MarginNet income ÷ Revenue+7.1%+5.2%
FCF MarginFCF ÷ Revenue+7.9%+14.0%
Rev. Growth (YoY)Latest quarter vs prior year+83.8%+1.4%
EPS Growth (YoY)Latest quarter vs prior year+4.8%+70.6%
BLLN leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PGNY leads this category, winning 6 of 6 comparable metrics.

At 41.0x trailing earnings, PGNY trades at a 97% valuation discount to BLLN's 1587.4x P/E. On an enterprise value basis, PGNY's 22.1x EV/EBITDA is more attractive than BLLN's 266.1x.

MetricBLLN logoBLLNBillionToOne, Inc.PGNY logoPGNYProgyny, Inc.
Market CapShares × price$4.7B$2.1B
Enterprise ValueMkt cap + debt − cash$4.3B$2.0B
Trailing P/EPrice ÷ TTM EPS1587.44x40.97x
Forward P/EPrice ÷ next-FY EPS est.102.72x20.82x
PEG RatioP/E ÷ EPS growth rate6.12x
EV / EBITDAEnterprise value multiple266.12x22.14x
Price / SalesMarket cap ÷ Revenue15.24x1.62x
Price / BookPrice ÷ Book value/share9.65x4.62x
Price / FCFMarket cap ÷ FCF295.98x10.88x
PGNY leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

PGNY leads this category, winning 6 of 8 comparable metrics.

PGNY delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $8 for BLLN. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to BLLN's 0.23x. On the Piotroski fundamental quality scale (0–9), BLLN scores 7/9 vs PGNY's 6/9, reflecting strong financial health.

MetricBLLN logoBLLNBillionToOne, Inc.PGNY logoPGNYProgyny, Inc.
ROE (TTM)Return on equity+7.6%+13.3%
ROA (TTM)Return on assets+5.1%+9.0%
ROICReturn on invested capital+13.5%+18.1%
ROCEReturn on capital employed+3.7%+17.4%
Piotroski ScoreFundamental quality 0–976
Debt / EquityFinancial leverage0.23x0.05x
Net DebtTotal debt minus cash-$387M-$88M
Cash & Equiv.Liquid assets$496M$112M
Total DebtShort + long-term debt$109M$24M
Interest CoverageEBIT ÷ Interest expense516.43x
PGNY leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

BLLN leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in BLLN five years ago would be worth $9,282 today (with dividends reinvested), compared to $4,131 for PGNY. Over the past 12 months, PGNY leads with a +23.6% total return vs BLLN's -7.2%. The 3-year compound annual growth rate (CAGR) favors BLLN at -2.5% vs PGNY's -12.3% — a key indicator of consistent wealth creation.

MetricBLLN logoBLLNBillionToOne, Inc.PGNY logoPGNYProgyny, Inc.
YTD ReturnYear-to-date+13.2%+3.5%
1-Year ReturnPast 12 months-7.2%+23.6%
3-Year ReturnCumulative with dividends-7.2%-32.6%
5-Year ReturnCumulative with dividends-7.2%-58.7%
10-Year ReturnCumulative with dividends-7.2%+67.1%
CAGR (3Y)Annualised 3-year return-2.5%-12.3%
BLLN leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

PGNY leads this category, winning 2 of 2 comparable metrics.

PGNY is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PGNY currently trades 92.6% from its 52-week high vs BLLN's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBLLN logoBLLNBillionToOne, Inc.PGNY logoPGNYProgyny, Inc.
Beta (5Y)Sensitivity to S&P 5001.91x0.61x
52-Week HighHighest price in past year$138.70$28.75
52-Week LowLowest price in past year$61.96$16.10
% of 52W HighCurrent price vs 52-week peak+72.9%+92.6%
RSI (14)Momentum oscillator 0–10056.564.6
Avg Volume (50D)Average daily shares traded642K1.4M
PGNY leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates BLLN as "Buy" and PGNY as "Buy". Consensus price targets imply 23.6% upside for BLLN (target: $125) vs 13.9% for PGNY (target: $30).

MetricBLLN logoBLLNBillionToOne, Inc.PGNY logoPGNYProgyny, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$125.00$30.33
# AnalystsCovering analysts420
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+3.9%
Insufficient data to determine a leader in this category.
Key Takeaway

PGNY leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). BLLN leads in 2 (Income & Cash Flow, Total Returns).

Best OverallProgyny, Inc. (PGNY)Leads 3 of 6 categories
Loading custom metrics...

BLLN vs PGNY: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is BLLN or PGNY a better buy right now?

For growth investors, BillionToOne, Inc.

(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 10. 4% for Progyny, Inc. (PGNY). Progyny, Inc. (PGNY) offers the better valuation at 41. 0x trailing P/E (20. 8x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — BLLN or PGNY?

On trailing P/E, Progyny, Inc.

(PGNY) is the cheapest at 41. 0x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, Progyny, Inc. is actually cheaper at 20. 8x.

03

Which is the better long-term investment — BLLN or PGNY?

Over the past 5 years, BillionToOne, Inc.

(BLLN) delivered a total return of -7. 2%, compared to -58. 7% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: PGNY returned +67. 1% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — BLLN or PGNY?

By beta (market sensitivity over 5 years), Progyny, Inc.

(PGNY) is the lower-risk stock at 0. 61β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately 214% more volatile than PGNY relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 23% for BillionToOne, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — BLLN or PGNY?

By revenue growth (latest reported year), BillionToOne, Inc.

(BLLN) is pulling ahead at 100. 0% versus 10. 4% for Progyny, Inc. (PGNY). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to 14. 0% for Progyny, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — BLLN or PGNY?

Progyny, Inc.

(PGNY) is the more profitable company, earning 4. 5% net margin versus 2. 4% for BillionToOne, Inc. — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 5. 3% for BLLN. At the gross margin level — before operating expenses — BLLN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is BLLN or PGNY more undervalued right now?

On forward earnings alone, Progyny, Inc.

(PGNY) trades at 20. 8x forward P/E versus 102. 7x for BillionToOne, Inc. — 81. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLLN: 23. 6% to $125. 00.

08

Which pays a better dividend — BLLN or PGNY?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is BLLN or PGNY better for a retirement portfolio?

For long-horizon retirement investors, Progyny, Inc.

(PGNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61)). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PGNY: +67. 1%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between BLLN and PGNY?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BLLN is a small-cap high-growth stock; PGNY is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.